Key facts
- This page summarizes Charles M. Watts's Form 4 filing for BIODESIX INC (BDSX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 23 May 2024, 19:15.
Charles M. Watts - 21 May 2024 Form 4 Insider Report for BIODESIX INC (BDSX)
- Reporting relationship
- Director
- Issuer ticker
- BDSX
- Reported as of
- 21 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 May 2024, 19:15:32 UTC
- Prior SEC filing
- 03 Apr 2024
- Next SEC filing
- 18 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robin H. Cowie as Attorney-in-Fact for Charles Watts
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Charles M. Watts filed Form 4 for BIODESIX INC (BDSX) on 23 May 2024.
Change
- Previous filing in this sequence was filed on 03 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BDSX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +46,686
- Change %
- Price
- $0.000000
- Shares after
- 46,686
- Date
- 21 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 46,686
- Exercise price
- Footnotes
- F1, F2
BDSX
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +37,050
- Change %
- Price
- $0.000000
- Shares after
- 37,050
- Date
- 21 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,050
- Exercise price
- $1.57
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.
Footnote F3
This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.